Company news
Abcellera Biologics Inc. (NASDAQ:ABCL) news
Abcellera Biologics Inc. news releases on 6ix. Latest, Sep 26, 2024: AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
Press releases — page 2
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
September 25, 2024
AbCellera to Present at Upcoming Investor Conferences in September
August 28, 2024
AbCellera Reports Q2 2024 Business Results
August 5, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
July 30, 2024
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
June 24, 2024
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
May 27, 2024
AbCellera Reports Q1 2024 Business Results
May 6, 2024
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
April 30, 2024
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
April 7, 2024
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
April 2, 2024
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
March 18, 2024
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
March 10, 2024
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
March 4, 2024
AbCellera Announces Resignation of Board Member
February 22, 2024
AbCellera to Present at Upcoming Investor Conferences in March
February 21, 2024
AbCellera Reports Full Year 2023 Business Results
February 19, 2024
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
January 22, 2024
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
December 19, 2023
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
November 15, 2023
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
November 2, 2023
AbCellera Reports Q3 2023 Business Results
November 1, 2023
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
October 31, 2023
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
October 30, 2023
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
October 10, 2023
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
September 26, 2023
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
September 19, 2023
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
September 12, 2023
AbCellera Reports Q2 2023 Business Results
August 2, 2023
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
July 23, 2023
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
July 5, 2023
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
May 28, 2023
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
May 23, 2023
AbCellera Reports Q1 2023 Business Results
May 3, 2023
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
April 16, 2023
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
April 10, 2023
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
April 5, 2023
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
March 21, 2023
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
March 13, 2023
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
February 22, 2023
AbCellera Reports Full Year 2022 Business Results
February 20, 2023
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
January 31, 2023
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
January 23, 2023
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
January 18, 2023
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
January 3, 2023
AbCellera and AbbVie Partner to Advance New Antibody Therapies
December 14, 2022
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
November 30, 2022
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
November 9, 2022
AbCellera Reports Q3 2022 Business Results
November 7, 2022
AbCellera to Present at Upcoming Investor Conferences in November
November 3, 2022
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
November 1, 2022